Abstracts

Clinical and developmental outcomes in the offspring of pregnant women with epilepsy taking novel anticonvulsants are unknown. Although researchers continue to accrue data through pregnancy registries, practitioner[apos]s caring for women of childbearing age may benefit from preliminary data. This case series summarizes the clinical and developmental outcomes in five offspring of women with epilepsy, all of whom took levetiracetam monotherapy during pregnancy. Offspring ages range from 4 months to 4 years., A retrospective chart review from maternal and pediatric medical records regarding clinical outcomes in the offspring of women taking levetiracetam monotherapy was conducted. Developmental, cognitive and physical milestone data were collected. Maternal information included gestational seizure frequency, serum concentration levels and other relevant data., Developmental milestones in five offspring of pregnant women with epilepsy taking levetiracetam monotherapy were reported. The women with epilepsy were seizure free during pregnancy. Maternal serum concentrations were therapeutic. All women took folic acid preconception and throughout their pregnancy. Data analysis revealed no cognitive or developmental abnormalities. Two siblings were diagnosed with cryptorchidism. No malignancies or additional physical or cognitive abnormalities were noted. No major or minor birth defects were recorded., This case series provides preliminary data. Due to the retrospective nature and small sample size, caution should be taken when interpreting the above outcomes. While future prospective studies with an adequate sample are mandatory, this case series may be encouraging for those seeking preliminary data on developmental outcomes in the offspring of pregnant women with epilepsy taking levetiracetam.,